USA - NASDAQ:CPIX - US2307701092 - Common Stock
The current stock price of CPIX is 2.11 USD. In the past month the price decreased by -38.66%. In the past year, price increased by 85.09%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 46.62 | 970.39B | ||
| JNJ | JOHNSON & JOHNSON | 18.88 | 471.87B | ||
| MRK | MERCK & CO. INC. | 10.55 | 232.09B | ||
| PFE | PFIZER INC | 7.83 | 142.48B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.11 | 94.95B | ||
| ZTS | ZOETIS INC | 19.06 | 53.55B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.53 | 22.84B | ||
| VTRS | VIATRIS INC | 4.6 | 12.50B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 21.97 | 10.48B | ||
| CORT | CORCEPT THERAPEUTICS INC | 85.84 | 7.96B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 6.97B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 4.07B |
Cumberland Pharmaceuticals, Inc. is a specialty pharmaceutical company, which focuses on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The company is headquartered in Nashville, Tennessee and currently employs 91 full-time employees. The company went IPO on 2009-08-11. The firm is focused on the acquisition, development and commercialization of branded prescription pharmaceutical products. Its portfolio of brands includes Acetadote (acetylcysteine) injection, for the treatment of acetaminophen poisoning; Caldolor (ibuprofen) injection, for the treatment of pain and fever; Kristalose (lactulose) for oral solution, a prescription laxative, for the treatment of constipation; Sancuso (granisetron) transdermal, for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment; Vaprisol (conivaptan) injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; and Vibativ (telavancin) injection, for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.
CUMBERLAND PHARMACEUTICALS
1600 West End Avenue, Suite 1300
Nashville TENNESSEE 37203 US
CEO: A. J. Kazimi
Employees: 91
Phone: 18774842700
Cumberland Pharmaceuticals, Inc. is a specialty pharmaceutical company, which focuses on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The company is headquartered in Nashville, Tennessee and currently employs 91 full-time employees. The company went IPO on 2009-08-11. The firm is focused on the acquisition, development and commercialization of branded prescription pharmaceutical products. Its portfolio of brands includes Acetadote (acetylcysteine) injection, for the treatment of acetaminophen poisoning; Caldolor (ibuprofen) injection, for the treatment of pain and fever; Kristalose (lactulose) for oral solution, a prescription laxative, for the treatment of constipation; Sancuso (granisetron) transdermal, for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment; Vaprisol (conivaptan) injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; and Vibativ (telavancin) injection, for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.
The current stock price of CPIX is 2.11 USD. The price increased by 0.96% in the last trading session.
CPIX does not pay a dividend.
CPIX has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
CPIX stock is listed on the Nasdaq exchange.
You can find the ownership structure of CUMBERLAND PHARMACEUTICALS (CPIX) on the Ownership tab.
ChartMill assigns a technical rating of 2 / 10 to CPIX. When comparing the yearly performance of all stocks, CPIX is one of the better performing stocks in the market, outperforming 87.06% of all stocks.
ChartMill assigns a fundamental rating of 3 / 10 to CPIX. The financial health of CPIX is average, but there are quite some concerns on its profitability.
Over the last trailing twelve months CPIX reported a non-GAAP Earnings per Share(EPS) of 0.1. The EPS increased by 158.82% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -4.32% | ||
| ROE | -10.47% | ||
| Debt/Equity | 0.19 |